Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Two-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Jun 30, 2026 21.76% = 16.06% × 1.35
Mar 31, 2026 22.41% = 16.38% × 1.37
Dec 31, 2025 21.18% = 15.42% × 1.37
Sep 30, 2025 21.22% = 14.78% × 1.44
Jun 30, 2025 21.18% = 15.13% × 1.40
Mar 31, 2025 -5.99% = -4.32% × 1.39
Dec 31, 2024 -3.26% = -2.38% × 1.37
Sep 30, 2024 -3.07% = -2.16% × 1.42
Jun 30, 2024 -3.32% = -2.43% × 1.36
Mar 31, 2024 21.67% = 16.81% × 1.29
Dec 31, 2023 20.59% = 15.92% × 1.29
Sep 30, 2023 21.01% = 15.97% × 1.32
Jun 30, 2023 21.75% = 16.54% × 1.32
Mar 31, 2023 22.59% = 17.18% × 1.31
Dec 31, 2022 23.88% = 18.30% × 1.30
Sep 30, 2022 25.12% = 19.59% × 1.28
Jun 30, 2022 26.77% = 20.50% × 1.31
Mar 31, 2022 22.47% = 17.19% × 1.31

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of the return on equity (ROE) reveals a performance trajectory primarily driven by fluctuations in asset efficiency rather than shifts in capital structure. Throughout the observed period, ROE mirrored the movement of the return on assets (ROA), indicating that the underlying profitability of the company's assets is the dominant factor in determining shareholder returns.

Return on Assets (ROA)
ROA exhibited a period of relative stability with a slight downward trend from 17.19% in March 2022 to 15.92% by December 2023. A significant volatility event occurred between June 2024 and March 2025, during which ROA shifted into negative territory, reaching a trough of -4.32% in March 2025. A recovery began in June 2025, with ROA returning to a range between 14.78% and 16.38% through June 2026.
Financial Leverage
Financial leverage remained consistently low and stable across the entire timeframe, fluctuating within a narrow band between 1.28 and 1.44. While a slight increase in leverage was observed during the period of negative asset returns, peaking at 1.44 in September 2025, the overall capital structure remained conservative. The leverage ratio did not serve as a significant driver of ROE volatility.
Return on Equity (ROE)
ROE tracked the movements of ROA closely due to the consistency of the leverage multiplier. After an initial range of 22.47% to 26.77% in 2022, ROE entered a negative phase between June 2024 and March 2025, reaching a minimum of -5.99%. Following this contraction, ROE recovered and stabilized between 21.18% and 22.41% from June 2025 through June 2026, reflecting a return to historical operational efficiency levels.

AI Ask an analyst for more



Three-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Jun 30, 2026 21.76% = 35.00% × 0.46 × 1.35
Mar 31, 2026 22.41% = 35.51% × 0.46 × 1.37
Dec 31, 2025 21.18% = 32.94% × 0.47 × 1.37
Sep 30, 2025 21.22% = 31.35% × 0.47 × 1.44
Jun 30, 2025 21.18% = 31.86% × 0.48 × 1.40
Mar 31, 2025 -5.99% = -8.91% × 0.49 × 1.39
Dec 31, 2024 -3.26% = -4.86% × 0.49 × 1.37
Sep 30, 2024 -3.07% = -4.52% × 0.48 × 1.42
Jun 30, 2024 -3.32% = -4.74% × 0.51 × 1.36
Mar 31, 2024 21.67% = 39.46% × 0.43 × 1.29
Dec 31, 2023 20.59% = 36.68% × 0.43 × 1.29
Sep 30, 2023 21.01% = 35.94% × 0.44 × 1.32
Jun 30, 2023 21.75% = 35.40% × 0.47 × 1.32
Mar 31, 2023 22.59% = 35.40% × 0.49 × 1.31
Dec 31, 2022 23.88% = 37.20% × 0.49 × 1.30
Sep 30, 2022 25.12% = 37.62% × 0.52 × 1.28
Jun 30, 2022 26.77% = 38.26% × 0.54 × 1.31
Mar 31, 2022 22.47% = 30.84% × 0.56 × 1.31

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Equity (ROE) exhibits a period of relative stability followed by a significant temporary contraction and a subsequent recovery. Between March 2022 and March 2024, ROE generally fluctuated between 20.59% and 26.77%. A sharp decline occurred starting in June 2024, with ROE falling into negative territory, reaching a low of -5.99% by March 2025, before returning to a stable range of 21.18% to 22.41% through June 2026.

Net Profit Margin
Profitability serves as the primary driver of ROE volatility. The margin remained strong and relatively consistent between 30.84% and 39.46% from March 2022 through March 2024. However, a severe downturn is observed from June 2024 to March 2025, where margins shifted to negative values, bottoming at -8.91%. A rapid recovery followed in June 2025, with margins returning to the 31% to 35% range, indicating that the period of losses was an isolated event rather than a long-term structural decline.
Asset Turnover
Asset efficiency shows a gradual downward trend over the observed period. The ratio declined from a peak of 0.56 in March 2022 to a low of 0.43 by December 2023. While there was a slight increase to 0.51 in June 2024, the ratio largely stabilized between 0.46 and 0.49 throughout 2025 and 2026. This suggests a slow decrease in the company's ability to generate revenue from its asset base, though the impact on ROE is secondary compared to profitability shifts.
Financial Leverage
The capital structure remained remarkably stable throughout the entire timeframe. Financial leverage fluctuated within a narrow band, primarily between 1.28 and 1.44. A slight increase in leverage was noted during the period of negative profitability, peaking at 1.44 in September 2025, before settling back to 1.35 by June 2026. The lack of significant movement in this component indicates that ROE fluctuations were not driven by changes in debt levels or equity financing.

Overall, the DuPont analysis reveals that the company's ROE is highly sensitive to net profit margins. The temporary collapse in ROE during 2024 and early 2025 was entirely attributable to a sharp decline in profitability, as asset turnover and financial leverage remained relatively constant. The restoration of ROE to levels exceeding 21% by mid-2025 coincides directly with the recovery of the net profit margin.

AI Ask an analyst for more



Five-Component Disaggregation of ROE

Vertex Pharmaceuticals Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Jun 30, 2026 21.76% = 0.84 × 1.00 × 41.96% × 0.46 × 1.35
Mar 31, 2026 22.41% = 0.84 × 1.00 × 42.36% × 0.46 × 1.37
Dec 31, 2025 21.18% = 0.85 × 1.00 × 38.80% × 0.47 × 1.37
Sep 30, 2025 21.22% = 0.83 × 1.00 × 38.06% × 0.47 × 1.44
Jun 30, 2025 21.18% = 0.83 × 1.00 × 38.45% × 0.48 × 1.40
Mar 31, 2025 -5.99% = × × -2.50% × 0.49 × 1.39
Dec 31, 2024 -3.26% = -2.16 × 0.89 × 2.53% × 0.49 × 1.37
Sep 30, 2024 -3.07% = -1.85 × 0.87 × 2.80% × 0.48 × 1.42
Jun 30, 2024 -3.32% = -2.28 × 0.84 × 2.48% × 0.51 × 1.36
Mar 31, 2024 21.67% = 0.84 × 0.99 × 47.23% × 0.43 × 1.29
Dec 31, 2023 20.59% = 0.83 × 0.99 × 44.83% × 0.43 × 1.29
Sep 30, 2023 21.01% = 0.81 × 0.99 × 45.10% × 0.44 × 1.32
Jun 30, 2023 21.75% = 0.78 × 0.99 × 45.81% × 0.47 × 1.32
Mar 31, 2023 22.59% = 0.78 × 0.99 × 45.83% × 0.49 × 1.31
Dec 31, 2022 23.88% = 0.78 × 0.99 × 48.01% × 0.49 × 1.30
Sep 30, 2022 25.12% = 0.81 × 0.99 × 46.95% × 0.52 × 1.28
Jun 30, 2022 26.77% = 0.81 × 0.99 × 47.81% × 0.54 × 1.31
Mar 31, 2022 22.47% = 0.86 × 0.98 × 36.80% × 0.56 × 1.31

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Equity (ROE) exhibits a pattern of stability between 20% and 27% from early 2022 through early 2024, followed by a significant contraction into negative territory throughout 2024 and early 2025. A full recovery to the 21% to 22% range is observed starting in mid-2025 and continuing through mid-2026. This volatility is primarily driven by fluctuations in operating profitability and tax burdens rather than changes in capital structure or asset efficiency.

Operating Profitability (EBIT Margin)
The EBIT margin remained robust, peaking at 48.01% in December 2022, before experiencing a severe collapse starting in June 2024, where it fell to 2.48% and reached a low of -2.50% by March 2025. This collapse is the primary catalyst for the negative ROE during this period. A recovery phase began in June 2025, with margins returning to a sustainable range of 38% to 42%.
Tax and Interest Burdens
The tax burden remained consistent around 0.80 until June 2024, at which point it became sharply negative, reaching -2.28. This indicates a significant tax credit or a non-recurring tax event that coincided with the operating margin decline. The interest burden remained near 1.00 for the majority of the period, suggesting minimal interest expense relative to earnings, though a brief dip to 0.84 was noted in June 2024.
Asset Turnover
A gradual downward trend in asset efficiency is observed from March 2022 (0.56) to March 2024 (0.43). This suggests that asset growth slightly outpaced revenue growth during this interval. However, the ratio stabilized between 0.46 and 0.51 from June 2024 onward, indicating a plateau in asset productivity.
Financial Leverage
Financial leverage remained remarkably stable, fluctuating within a narrow band between 1.28 and 1.44. There was a slight upward trend in leverage toward September 2025 (1.44) before it moderated to 1.35 by June 2026. The consistency of this ratio indicates that changes in ROE were not the result of aggressive shifts in debt financing.

In summary, the financial profile is characterized by high operating margins and low leverage. The anomalous period between June 2024 and March 2025 represents a significant departure from historical norms, driven by a collapse in EBIT margins and unusual tax adjustments, though the subsequent return to previous ROE levels suggests these were transitory factors.

AI Ask an analyst for more



Two-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Jun 30, 2026 16.06% = 35.00% × 0.46
Mar 31, 2026 16.38% = 35.51% × 0.46
Dec 31, 2025 15.42% = 32.94% × 0.47
Sep 30, 2025 14.78% = 31.35% × 0.47
Jun 30, 2025 15.13% = 31.86% × 0.48
Mar 31, 2025 -4.32% = -8.91% × 0.49
Dec 31, 2024 -2.38% = -4.86% × 0.49
Sep 30, 2024 -2.16% = -4.52% × 0.48
Jun 30, 2024 -2.43% = -4.74% × 0.51
Mar 31, 2024 16.81% = 39.46% × 0.43
Dec 31, 2023 15.92% = 36.68% × 0.43
Sep 30, 2023 15.97% = 35.94% × 0.44
Jun 30, 2023 16.54% = 35.40% × 0.47
Mar 31, 2023 17.18% = 35.40% × 0.49
Dec 31, 2022 18.30% = 37.20% × 0.49
Sep 30, 2022 19.59% = 37.62% × 0.52
Jun 30, 2022 20.50% = 38.26% × 0.54
Mar 31, 2022 17.19% = 30.84% × 0.56

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Assets (ROA) exhibits a volatile trend characterized by a period of stability, a sharp contraction, and a subsequent recovery. The overall performance of ROA is primarily driven by fluctuations in net profit margins rather than changes in asset utilization efficiency.

Net Profit Margin
A period of strong profitability is observed from March 2022 through March 2024, with margins generally fluctuating between 30.84% and a peak of 39.46%. However, a significant anomaly occurs between June 2024 and March 2025, where margins drop sharply into negative territory, reaching a low of -8.91%. Following this downturn, a recovery is evident starting in June 2025, with margins returning to a stable range between 31.35% and 35.51% through June 2026.
Asset Turnover
Asset turnover demonstrates a gradual and consistent downward trend over the analyzed period. Starting at 0.56 in March 2022, the ratio declines to 0.43 by December 2023. From March 2024 through June 2026, the ratio remains relatively stagnant, oscillating narrowly between 0.43 and 0.51. This suggests a slight decrease in the efficiency of assets in generating revenue, though the impact is far less volatile than the margin shifts.
Return on Assets (ROA) Disaggregation
The two-component analysis reveals that ROA is highly sensitive to profitability shocks. During the peak performance in mid-2022, ROA reached 20.50%, supported by both high margins and higher asset turnover. The contraction of ROA to a minimum of -4.32% in March 2025 is directly attributable to the negative net profit margins, as asset turnover remained relatively stable during that same period. The recovery of ROA to 16.06% by June 2026 mirrors the restoration of profit margins, confirming that margin expansion is the dominant driver of return on assets for the entity.

AI Ask an analyst for more



Four-Component Disaggregation of ROA

Vertex Pharmaceuticals Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Jun 30, 2026 16.06% = 0.84 × 1.00 × 41.96% × 0.46
Mar 31, 2026 16.38% = 0.84 × 1.00 × 42.36% × 0.46
Dec 31, 2025 15.42% = 0.85 × 1.00 × 38.80% × 0.47
Sep 30, 2025 14.78% = 0.83 × 1.00 × 38.06% × 0.47
Jun 30, 2025 15.13% = 0.83 × 1.00 × 38.45% × 0.48
Mar 31, 2025 -4.32% = × × -2.50% × 0.49
Dec 31, 2024 -2.38% = -2.16 × 0.89 × 2.53% × 0.49
Sep 30, 2024 -2.16% = -1.85 × 0.87 × 2.80% × 0.48
Jun 30, 2024 -2.43% = -2.28 × 0.84 × 2.48% × 0.51
Mar 31, 2024 16.81% = 0.84 × 0.99 × 47.23% × 0.43
Dec 31, 2023 15.92% = 0.83 × 0.99 × 44.83% × 0.43
Sep 30, 2023 15.97% = 0.81 × 0.99 × 45.10% × 0.44
Jun 30, 2023 16.54% = 0.78 × 0.99 × 45.81% × 0.47
Mar 31, 2023 17.18% = 0.78 × 0.99 × 45.83% × 0.49
Dec 31, 2022 18.30% = 0.78 × 0.99 × 48.01% × 0.49
Sep 30, 2022 19.59% = 0.81 × 0.99 × 46.95% × 0.52
Jun 30, 2022 20.50% = 0.81 × 0.99 × 47.81% × 0.54
Mar 31, 2022 17.19% = 0.86 × 0.98 × 36.80% × 0.56

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The Return on Assets (ROA) demonstrates a period of relative stability followed by a significant contraction in 2024 and a subsequent recovery by mid-2025. From March 2022 through March 2024, ROA fluctuated between 15.92% and 20.50%, before plummeting to negative values ranging from -2.16% to -4.32% between June 2024 and March 2025. Performance normalized starting in June 2025, returning to a range of 14.78% to 16.38% through June 2026.

EBIT Margin
Operational profitability served as the primary driver of ROA volatility. The EBIT margin remained robust between 36.80% and 48.01% for the majority of the observed period. However, a severe compression occurred starting June 2024, where margins collapsed to approximately 2.5% and reached a low of -2.50% by March 2025. A recovery to levels between 38.06% and 42.36% was observed from June 2025 onward, indicating a restoration of core operating efficiency.
Tax Burden
The tax burden remained consistently between 0.78 and 0.86 for most quarters, signifying a stable effective tax rate. A notable anomaly appeared between June 2024 and December 2024, where the ratio turned sharply negative, reaching as low as -2.28. This suggests the recognition of significant tax benefits or credits during the period of operating losses, which partially offset the decline in net income.
Interest Burden
The interest burden remained near 1.00 for most of the timeline, indicating that interest expenses had a negligible impact on EBIT. A slight decrease to a range of 0.84 to 0.89 occurred during the 2024 downturn, reflecting a higher relative impact of interest costs as EBIT declined, although the burden returned to 1.00 by June 2025.
Asset Turnover
Asset utilization exhibited a gradual downward trend in the early phase of the analysis, declining from 0.56 in March 2022 to 0.43 by March 2024. Following this decline, the ratio stabilized, fluctuating narrowly between 0.44 and 0.51. This indicates that while asset efficiency decreased initially, it remained constant regardless of the volatility seen in profit margins.

The overall analysis indicates that the temporary collapse in ROA was not a result of asset inefficiency or debt costs, but was driven almost entirely by a sharp, transient decline in the EBIT margin, which was partially mitigated by favorable tax adjustments.

AI Ask an analyst for more



Disaggregation of Net Profit Margin

Vertex Pharmaceuticals Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Jun 30, 2026 35.00% = 0.84 × 1.00 × 41.96%
Mar 31, 2026 35.51% = 0.84 × 1.00 × 42.36%
Dec 31, 2025 32.94% = 0.85 × 1.00 × 38.80%
Sep 30, 2025 31.35% = 0.83 × 1.00 × 38.06%
Jun 30, 2025 31.86% = 0.83 × 1.00 × 38.45%
Mar 31, 2025 -8.91% = × × -2.50%
Dec 31, 2024 -4.86% = -2.16 × 0.89 × 2.53%
Sep 30, 2024 -4.52% = -1.85 × 0.87 × 2.80%
Jun 30, 2024 -4.74% = -2.28 × 0.84 × 2.48%
Mar 31, 2024 39.46% = 0.84 × 0.99 × 47.23%
Dec 31, 2023 36.68% = 0.83 × 0.99 × 44.83%
Sep 30, 2023 35.94% = 0.81 × 0.99 × 45.10%
Jun 30, 2023 35.40% = 0.78 × 0.99 × 45.81%
Mar 31, 2023 35.40% = 0.78 × 0.99 × 45.83%
Dec 31, 2022 37.20% = 0.78 × 0.99 × 48.01%
Sep 30, 2022 37.62% = 0.81 × 0.99 × 46.95%
Jun 30, 2022 38.26% = 0.81 × 0.99 × 47.81%
Mar 31, 2022 30.84% = 0.86 × 0.98 × 36.80%

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of the net profit margin disaggregation reveals a period of stability and growth, followed by a significant operational disruption between June 2024 and March 2025, and a subsequent recovery through June 2026.

Operating Profitability (EBIT Margin)
The EBIT margin served as the primary driver of profitability volatility. From March 2022 to March 2024, the margin remained robust, peaking at 48.01% in December 2022. A sharp contraction occurred in the second quarter of 2024, where the margin fell to 2.48% and eventually reached a low of -2.50% by March 2025. A recovery phase ensued, with the margin returning to 41.96% by June 2026.
Interest Burden
The interest burden remained highly stable and near unity (0.98 to 1.00) for the majority of the observed period, indicating that interest expenses had a negligible impact on the transition from EBIT to pre-tax income. A temporary dip was observed between June 2024 (0.84) and December 2024 (0.89), coinciding with the period of depressed operating income.
Tax Burden
The tax burden ratio generally fluctuated within a narrow range of 0.78 to 0.86. However, significant anomalies occurred between June 2024 and December 2024, where the ratio turned negative, reaching -2.28 in June 2024. These negative values suggest the realization of substantial tax credits or deferred tax assets during the period of operational loss, which partially mitigated the impact on net income.
Net Profit Margin
The net profit margin closely tracked the movements of the EBIT margin. After an upward trend that peaked at 39.46% in March 2024, the margin experienced a severe decline, reaching a minimum of -8.91% in March 2025. Profitability recovered starting in June 2025 (31.86%) and trended steadily upward to 35.00% by June 2026, returning the organization to a normalized profit profile.

AI Ask an analyst for more